CFTR and cystic fibrosis: These findings position RFFL ASO as a promising first-in-class CFTR stabilizer that can potentiate the efficacy of CFTR modulators, and a potential therapeutic agent for CF patients with class VI CFTR mutations including ΔF508-CFTR and rare mutants.